September 03, 2026 – NEW YORK -- Egan-Jones Ratings Co. released an analysis showing how a fixed income investor can select a top-tier issuer, complete rigorous due diligence, and still lose roughly half a position's value.

Apple's 2060 notes have lost half their value since issuance

The commentary centers on Apple's 2.55 percent senior notes due 2060, issued in August 2020 at approximately par. The notes traded near 68 percent of par in December 2023 and have since fallen to about half of par, quoted at 50.92 on the Frankfurt Stock Exchange on August 27, 2026.

September 03, 2026 – GUANGZHOU -- Guangzhou Shangpin Packaging Products Co., Ltd. (Sprintpackage) has increased its annual production output by two to three times after relocating to a new 20,000-square-meter automated facility in the No. 1 Hard Technology Industrial Park, Baiyun District, Guangzhou, completed in June 2026.

Six automated lines push daily output to 300,000 units

The paper tube manufacturer installed six fully automated production lines covering tube winding, slitting, paper mounting, curling, and final assembly. Factory engineers added a new fleet of automatic tube winding machines, paper mounting equipment, rotary curling units, and high-speed assembly systems ahead of the plant opening. With automation exceeding 80%, the facility now produces between 200,000 and 300,000 paper tube units daily, supplying wholesale buyers across Europe and the Middle East.

September 03, 2026 – Dublin -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit over trastuzumab plus chemotherapy in first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma (GEA), based on a second interim analysis of the Phase 3 HERIZON-GEA-01 trial.

Ziihera's survival hazard ratio improved from the first interim analysis

The Ziihera plus chemotherapy arm showed an improved OS hazard ratio compared with the trial's first interim readout, according to Jazz. The company said the safety profile remained consistent with prior HERIZON-GEA-01 data and each agent's known profile, with no new safety signals identified.

September 03, 2026 – Guangzhou -- Guangzhou Shangpin Packaging Products Co., Ltd. (Sprintpackage) has doubled to tripled its annual paper tube production output after relocating operations to a new 20,000-square-meter facility in the No. 1 Hard Technology Industrial Park, Baiyun District, Guangzhou, completed in June 2026.

Six automated lines push daily capacity to 300,000 units

The new plant runs six fully automated production lines covering tube winding, slitting, paper mounting, curling, and final assembly in-house. With automation exceeding 80%, Sprintpackage now produces between 200,000 and 300,000 tube units daily, supplying buyers primarily across Europe and the Middle East.

September 03, 2026 – Summerlin, Nev. -- FaceTec, Inc. has released its UR® Codes August 2026 Update, detailing three law-enforcement and public-safety organizations now running the biometric identity credential in live deployments across the United States.

Albany County deputies gain instant cross-jurisdictional ID verification

The Albany County Sheriff's Office has upgraded standard Deputy ID cards with UR Codes, allowing partner agencies or citizens to instantly verify a deputy's identity and blocking use of lost, stolen or counterfeit credentials.

Saratoga County enables offline verification for retired officers carrying concealed firearms

The Saratoga County Sheriff's Office uses UR Codes to let out-of-state officers biometrically confirm a retiree's active qualification under the federal Law Enforcement Officers Safety Act (LEOSA/HR218), without requiring a network connection or centralized database check.

September 03, 2026 – Melbourne -- SIBIONICS showcased its AI-driven continuous glucose monitoring (CGM) sensor, GS3, at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress in Melbourne, held August 18-21 and featuring a company booth, a scientific symposium and on-site interviews with certified diabetes educators (CDEs).

GS3 sensor delivers 14-day monitoring with a 2.9mm profile

The factory-calibrated GS3 sensor is designed for continuous glucose tracking over a 14-day cycle while minimizing physical discomfort through its slim 2.9mm profile. SIBIONICS positioned the device as an extension of its work in brain-computer interfaces, including a retinal prosthesis for patients with retinitis pigmentosa, adapting high-precision biosensor and signal-processing engineering into a more accessible CGM platform.

September 03, 2026 – Vancouver, BC -- Defense Metals Corp. (TSXV: DEFN; OTCQB: DFMTF; FSE:35D) reported assay results from an initial eleven core drill holes totaling 1,633 metres at its 100%-owned Wicheeda Rare Earth Project near Prince George, British Columbia, with hole WI26-96 returning 2.86% Total Rare Earth Oxide (TREO) over 65 metres, including a higher-grade interval of 6.15% TREO over 20.3 metres.

September 03, 2026 – Houston -- Summit Midstream Corporation (NYSE: SMC) has reached a final investment decision on a mainline compression expansion for its Double E Pipeline, backed by a new 200 MMcf/d take-or-pay agreement with an investment-grade shipper that lifts total contracted firm capacity on the system to approximately 2.2 Bcf/d.

September 03, 2026 – INDIANAPOLIS -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

Combination therapy nearly triples complete skin clearance response rates

In the TOGETHER-PsO trial, 30.6% of patients on the combination achieved PASI 100 plus at least 10% weight loss at Week 52, compared with 4.4% on Taltz monotherapy. Complete skin clearance alone (PASI 100) was maintained by 40.5% of combination patients versus 29.1% on monotherapy.

September 03, 2026 – Dublin -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

OS hazard ratio for Ziihera plus chemotherapy improved versus the first interim analysis

The company said the survival advantage strengthened compared with earlier data, reinforcing Ziihera's position following its FDA approval on August 25, 2026. No new safety signals emerged relative to previously reported HERIZON-GEA-01 data or the known profiles of the individual agents.